ECOR - electroCore, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.40
+0.64 (+11.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 5.76
Open 5.77
Bid 5.01 x 800
Ask 6.54 x 1800
Day's Range 5.77 - 6.40
52 Week Range 4.16 - 20.25
Volume 30,282
Avg. Volume 129,604
Market Cap 188.48M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -1.19
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 22.25
Trade prices are not sourced from all markets
  • GlobeNewswire 23 days ago

    electroCore Announces Fourth Quarter and Full Year 2018 Financial Results

    BASKING RIDGE, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter and full year 2018 financial results and provided an operational update. “During the fourth quarter, we continued to execute on our commercial growth plan, led by our ongoing progress toward increasing covered lives through productive discussions with national and regional payers,” said Frank Amato, Chief Executive Officer of electroCore.

  • GlobeNewswire last month

    electroCore to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Wednesday, March 27

    BASKING RIDGE, N.J., March 18, 2019 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will report fourth quarter.

  • GlobeNewswire last month

    electroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™

    BASKING RIDGE, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a global commercial-stage bioelectronic medicine company, today announced new preclinical and clinical research supporting the potential therapeutic benefit of its non-invasive vagus nerve stimulator (nVNS), gammaCoreTM, for the treatment of mild traumatic brain injury (mTBI) and rheumatoid arthritis (RA). “The recent results are very encouraging as they support the broad therapeutic potential of nVNS therapy,” said Francis Amato, chief executive officer of electroCore.

  • 4 Stocks Join Ben Graham Net-Net Screener Friday
    GuruFocus.com last month

    4 Stocks Join Ben Graham Net-Net Screener Friday

    While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active

  • GlobeNewswire last month

    UPDATE - electroCore Appointments Multiple Industry Veterans to Key Management Positions

    BASKING RIDGE, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr. Tony Fiorino as chief medical officer and Brian Posner as chief financial officer. The company’s current chief medical officer, Dr. Peter Staats, will become a senior executive advisor of Medical and Government Affairs.

  • GlobeNewswire last month

    electroCore Appointments Multiple Industry Veterans to Key Management Positions

    BASKING RIDGE, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr. Tony Fiorino as chief medical officer and Brian Posner as chief financial officer. The company’s current chief medical officer, Dr. Peter Staats, will become a senior executive advisor of Medical and Government Affairs.

  • GlobeNewswire 2 months ago

    electroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark

    BASKING RIDGE, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Highmark, one of the nation’s top health insurers and the third largest Blue Cross Blue Shield affiliated company, has determined that non-implantable vagus nerve stimulation device, gammaCore, may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches.

  • GlobeNewswire 2 months ago

    electroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies

    The initiative is driven by results from an electroCore-HealthyWomen partnered survey, which showed there is a significant lack of awareness of non-drug treatment options for migraine among female patients. According to the survey of over 1,000 female migraine patients between the ages of 18 and 60 years old, 86 percent of patients are completely or somewhat willing to try non-drug treatments, however, only 36 percent expressed awareness of non-drug treatment options. To bridge this knowledge gap surrounding the availability and utility of non-drug treatment options, HealthyWomen and electroCore have developed a suite of content which can be found at HealthyWomen.org/migraine designed to educate women who suffer from migraine and to empower them to initiate a conversation with their HCP about the use of non-drug therapies in their own treatment plan.

  • ACCESSWIRE 3 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • GlobeNewswire 3 months ago

    electroCore to Present at Noble Capital Markets’ Fifteenth Annual Investor Conference

    BASKING RIDGE, N.J., Jan. 28, 2019 -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive.

  • GlobeNewswire 3 months ago

    electroCore Announces Two New Studies and a Publication Supporting the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults

    BASKING RIDGE, N.J., Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding the use of non-invasive vagus nerve stimulation (nVNS) for the acute and preventive treatment of migraine, and a recent publication of a real-world retrospective analysis which supports the use of nVNS as an effective therapeutic option for patients with cluster headache. “We are committed to expanding our knowledge of the utility of nVNS for the treatment of primary headache disorders. Through the published paper which supports the real-world effectiveness of gammaCore in cluster headache, and the initiation of two important new trials in migraine, we are continually deepening our understanding of the ability of nVNS to address unmet needs among migraine and cluster headache patients,” said Peter S. Staats, M.D., Chief Medical Officer, electroCore.

  • GlobeNewswire 4 months ago

    gammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule (FSS)

    With the FSS contract, we will deepen our commitment to the underserved patient population diagnosed with migraine or cluster headache, and are one step closer to ensuring patients who may benefit from gammaCore have access to this safe and effective therapy,” said Frank Amato, Chief Executive Officer, electroCore. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs.

  • Is electroCore, Inc.’s (NASDAQ:ECOR) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St. 4 months ago

    Is electroCore, Inc.’s (NASDAQ:ECOR) Balance Sheet Strong Enough To Weather A Storm?

    The direct benefit for electroCore, Inc. (NASDAQ:ECOR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...

  • GlobeNewswire 5 months ago

    electroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults

    BASKING RIDGE, N.J., Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded label for gammaCore™ [non-invasive vagus nerve stimulator (nVNS)] therapy for adjunctive use for the preventive treatment of cluster headache in adult patients. This milestone marks the first and only product FDA cleared for the prevention of cluster headache. There are currently no FDA-approved pharmacologic treatments for the prevention of cluster headache.

  • ACCESSWIRE 5 months ago

    FDA Changes Will Reward Medical Device Innovation: Here’s What Investors Need to Know

    The U.S. FDA plans a major overhaul of how medical devices are regulated and approved in the United States. The changes are intended to keep unsafe products off the market and reward innovation from medical device companies. One medical device ETF has almost tripled the performance of the S&P 500 since its inception.

  • GlobeNewswire 5 months ago

    electroCore Expands Manufacturing Capabilities for gammaCore™

    BASKING RIDGE, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus nerve stimulator product. “We are pleased to announce expansion into this new design, development and manufacturing facility which will ensure we can meet growing patient demand for gammaCore,” said Frank Amato, Chief Executive Officer of electroCore.

  • GlobeNewswire 5 months ago

    Market Trends Toward New Normal in Tandy Leather Factory, Boxlight, Willamette Valley Vineyards, electroCore, FAT Brands, and Village Super Market — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire 5 months ago

    electroCore, Inc. to Present at the Evercore ISI HealthCONx Conference

    BASKING RIDGE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Evercore ISI HealthCONx Conference in Boston, MA. Actual results could differ from those projected in any forward-looking statements due to numerous factors.

  • GlobeNewswire 5 months ago

    electroCore, Inc. Announces Third Quarter Financial Results

    BASKING RIDGE, N.J., Nov. 13, 2018 -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for.

  • GlobeNewswire 5 months ago

    NICE publishes advice on gammaCore for the treatment of cluster headache in the UK

    BASKING RIDGE, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) --  electroCore, Inc., commercial-stage bioelectronic company, today announced that the National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on their non-invasive vagus nerve stimulator (nVNS), gammaCore, for use in the treatment of cluster headache in adults. The report collates the most recent published evidence, and surmises that gammaCore is beneficial for people suffering with cluster headache.

  • GlobeNewswire 6 months ago

    electroCore, Inc. to Report Third Quarter Financial Results on November 13, 2018

    BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the third quarter ended September 30, 2018 after the close of trading on Tuesday, November 13, 2018.  The company’s management team will host a corresponding conference call beginning at 4:30 PM ET. Investors interested in listening to the conference call may do so by dialing (877) 371-5740 for domestic callers or (629) 228-0724 for international callers, using Conference ID: 5067968. A live webcast of the event will be available on the “Investors” section of the company’s website at: www.electrocore.com.

  • GlobeNewswire 6 months ago

    electroCore, Inc. Announces Appointment of Ardelle Ferris as Vice President of Managed Care

    BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the company, Vice President of Managed Care. Ardelle brings over 20 years of experience in national account management with PBMs and commercial health plans.

  • Who Really Owns electroCore Inc (NASDAQ:ECOR)?
    Simply Wall St. 7 months ago

    Who Really Owns electroCore Inc (NASDAQ:ECOR)?

    If you want to know who really controls electroCore Inc (NASDAQ:ECOR), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...